
MaaT Pharma Receives Negative CHMP Trend Vote for MaaT013 (Xervyteg®) Following Re-Examination for its Conditional Marketing Authorization Application in Europe
<a href="https://news.google.com/rss/articles/CBMiowJBVV95cUxPQWotSUtlZ0dmUGpYYWI5c002dnoza3U2VUlYNFZvSEZjcXpyeHo3MGpCYkJscGdBZ1FnMlg1S2g4a0xMQ3V5WkJ3cGhOZzFiTGcybnVwU1JVUTZIVm9lRGRsZ0paLWEtVE0tM1NKZENRa2Z3NHZzOWZBaVRMc01walVyVXJRXzNxelJJTjNnMURpakMwREJta0ZINVBod3RaU21SeVo2SmNnWHFfdzRGQTlLb3oyS2FTelkzNHdlTTJRTmxMVWV1cTdha0FYSFlNS2J0Q3kzVExXU1ZKZFEtSFFzSlJIUDZoOHgtbnlFYUtkWC16RUVFMHlxZlhxUm5YMlF1d0ZBa2JqT3RSdDlfRTRMX1YwU3RTX3ducUN6eTBsZEU?oc=5" target="_blank">MaaT Pharma Receives Negative CHMP Trend Vote for MaaT013 (Xervyteg®) Following Re-Examination for its Conditional Marketing Authorization Application in Europe</a>&nbsp;&nbsp;<font color="#6f6f6f">BioSpace</font>

